AI Heart-Mapping Tech from Cara Medical Wins FDA Clearance

TORTOLA, British Virgin Islands – February 25, 2026 – The U.S. Food and Drug Administration has granted clearance to a groundbreaking medical technology that uses artificial intelligence to create a personalized 3D map of the heart's electrical wiring, potentially ushering in a new era of precision for complex cardiac procedures. Cara Medical Ltd. announced today it received 510(k) clearance for its CARA System, a noninvasive platform designed to help surgeons visualize and navigate the heart’s delicate conduction system.

The clearance marks a significant milestone for the company and for the field of interventional cardiology, where avoiding damage to this critical network of cells is paramount. The system, which previously earned the FDA's prestigious Breakthrough Device Designation, is poised to enter the U.S. market in the coming months, targeting the rapidly growing sectors of structural heart repair and advanced cardiac pacing.

A New Map for the Heart's Electrical Maze

For decades, interventional cardiologists have performed intricate procedures like valve replacements and pacemaker implantations by relying on anatomical landmarks and live X-ray (fluoroscopy), often flying blind when it comes to the heart's electrical pathways. The cardiac conduction system—the network responsible for generating and coordinating every heartbeat—is typically invisible on standard imaging, making it vulnerable to accidental injury during interventions. Such damage can lead to serious complications, most notably the need for a permanent pacemaker.

The CARA System is designed to solve this fundamental problem by rendering the invisible, visible. It integrates two sophisticated components to provide a comprehensive solution for both planning and execution of cardiac procedures.

First, the CARA Metis™ Simulator acts as a pre-procedural architect. Using data from a standard computed tomography angiography (CTA) scan, the software employs advanced image processing and proprietary AI algorithms to analyze anatomical landmarks. From this analysis, it generates a patient-specific, three-dimensional model of the cardiac conduction system, effectively creating a detailed electrical road map unique to that individual's heart.

Once in the operating room, the CARA Atlas™ Navigator takes over. This intraprocedural guidance platform seamlessly overlays the 3D map generated by Metis onto the live fluoroscopic images being used by the physician. This augmented reality approach allows surgeons to see, for the first time, the precise location of the conduction system in real-time relative to their instruments and the surrounding cardiac structures.

Revolutionizing Precision in Cardiac Interventions

The technology's applications are particularly relevant for two of the most dynamic areas in modern cardiology: transcatheter aortic valve replacement (TAVR) and conduction system pacing (CSP).

In TAVR procedures, where a new heart valve is deployed within a diseased one, the proximity of the deployment zone to the conduction system creates a significant risk. The CARA System aims to enhance procedural precision, allowing physicians to plan valve placement that minimizes interaction with these sensitive tissues. This could potentially reduce the rate of post-TAVR pacemaker implantations, a common complication that affects patient outcomes and increases healthcare costs.

For conduction system pacing, an emerging field that seeks to provide more physiologic heart stimulation, the CARA System offers a tool for direct targeting. Instead of placing pacemaker leads in arbitrary locations, physicians can use the 3D map to guide leads to specific, optimal locations within the patient's own conduction system, potentially leading to better long-term cardiac function.

"This FDA clearance represents a significant milestone for Cara Medical," said Shlomo Ben-Haim, MD, Founder and Chairman of Cara Medical Ltd., in a statement. "We look forward to launching the product in the United States and providing physicians with a validated tool designed to enhance visualization of the cardiac conduction axis. Our growing body of clinical publications highlights Cara's potential role in supporting procedural precision during TAVR and other valve interventions, and in facilitating physiologic lead targeting during conduction system pacing."

Navigating a Multi-Billion Dollar Market

Securing 510(k) clearance is a critical step that unlocks the door to the vast U.S. healthcare market. The prior Breakthrough Device Designation from the FDA in 2025 had already signaled the technology's potential to provide a more effective diagnosis or treatment for life-threatening conditions, likely expediting its review process.

Cara Medical now enters a competitive but lucrative space. The global market for structural heart devices is valued in the billions and continues to expand as minimally invasive procedures become the standard of care. The CARA System's unique selling proposition is its ability to provide this crucial visualization non-invasively from a CTA scan that is often already part of the patient's pre-procedural workup. This distinguishes it from invasive electrophysiological mapping systems and offers a significant upgrade over relying on anatomical inference alone.

The company's software-based platform, which operates on a standard workstation and integrates with existing hospital equipment, is designed to lower the barrier to entry for hospitals. By avoiding the need for new, dedicated capital equipment and having no direct contact with the patient, the system presents a potentially streamlined path to adoption.

The Path to Adoption: Promise and Hurdles

While the technological promise is clear, the success of the CARA System will ultimately depend on its real-world performance and adoption by the medical community. The company's U.S. commercial launch will target major medical centers with established structural heart and electrophysiology programs.

Key challenges will include navigating hospital procurement processes and demonstrating clear value. While the system is designed to integrate with existing workflows, any new technology requires a learning curve for physicians and their teams. Widespread adoption will hinge on the company's ability to provide robust clinical data from post-market studies that definitively link the use of the system to improved patient outcomes, such as lower pacemaker rates, shorter procedure times, and enhanced safety.

Physician confirmation of the AI-generated outputs remains a crucial step in the process, maintaining clinical oversight while leveraging the power of machine learning. As healthcare providers gain experience with the system, its ability to consistently and accurately map the conduction system will be the ultimate test of its value. If successful, the technology could fundamentally change the standard of care, moving cardiac interventions from an art of anatomical approximation to a science of personalized, image-guided precision.